Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Relievant Medsystems, Inc. for $850 million on September 19, 2023. The transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years. The transaction is expected to close in H1, 2024. On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share (EPS) in 2024, slightly accretive in 2025, and increasingly accretive thereafter. Matt Stamski, Brandon C. Mason, Vanessa S. Tabler, Gayle L. Skolnik, Reed Abrahamson, Amy L. Johnson, Steve Lokensgard, Timothy E. Grimsrud, Robert B. Leonard, Daniel G. Prokott, Rhiannon C. Beckendorf, B. Shane Barnes and Sean M. FitzGerald of Faegre Drinker Biddle & Reath LLP acted as legal advisor to Boston Scientific. Charles Ruck, Saad Khanani, Kathleen Wells, Heather Deixler, Christopher Hazuka, Joshua Holian, Patrick English, Ben Haas, Betty Pang, Erin Brown Jones, Andrew Galdes, Kirt Switzer, and Ashley Wagner of Latham & Watkins LLP Advised Relievant MedSystems in the deal.

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Relievant Medsystems, Inc. on November 17, 2023.